ADAR1 Capital Management LLC Purchases 888,602 Shares of Taysha Gene Therapies, Inc. $TSHA

Key Points

• ADAR1 Capital Management LLC increased its stake in Taysha Gene Therapies by 500%, owning approximately 1,066,309 shares worth $1.48 million as of its latest filing.
• Several other institutional investors significantly boosted their holdings in Taysha Gene Therapies, with Bank of America Corp DE increasing its stake by 1,178.9%.
• Taysha Gene Therapies reported a quarterly loss of ($0.09) EPS, missing analyst estimates, and had a negative net margin of 1,144.97%.

ADAR1 Capital Management LLC lifted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 500.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,066,309 shares of the company's stock after buying an additional 888,602 shares during the period. ADAR1 Capital Management LLC owned approximately 0.52% of Taysha Gene Therapies worth $1,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC purchased a new position in shares of Taysha Gene Therapies in the 1st quarter worth $760,000. Hsbc Holdings PLC lifted its position in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Taysha Gene Therapies during the fourth quarter valued at $41,000. Millennium Management LLC purchased a new position in Taysha Gene Therapies during the fourth quarter valued at $262,000. Finally, Barclays PLC lifted its position in Taysha Gene Therapies by 35.6% during the fourth quarter. Barclays PLC now owns 335,238 shares of the company's stock valued at $587,000 after purchasing an additional 87,958 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA traded up $0.36 on Thursday, reaching $3.26. 14,217,441 shares of the company's stock traded hands, compared to its average volume of 2,624,493. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $3.31. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a 50-day simple moving average of $2.71 and a 200-day simple moving average of $2.24. The firm has a market cap of $889.33 million, a PE ratio of -9.59 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The firm had revenue of $1.99 million during the quarter, compared to the consensus estimate of $1.61 million. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on TSHA shares. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, June 3rd. JMP Securities lifted their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research report on Thursday, May 29th. Bank of America started coverage on Taysha Gene Therapies in a research report on Friday, July 11th. They set a "buy" rating and a $8.00 target price on the stock. Finally, Citigroup reissued an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $8.29.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.